Positron emission tomography of striatal serotonin transporters in Parkinson disease

Archives of Neurology

Volumn 60, Issue 9, 2003, Pages 1223-1229

  Kerenyi, Levente ^a   Ricaurte, George A ^c   Schretlen, David J ^d   McCann, Una ^d   Varga, Jozsef ^b   Mathews, William B ^e   Ravert, Hayden T ^c   Dannals, Robert F ^c   Hilton, John ^c   Wong, Dean F ^c   Szabo, Zsolt ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOLIGAND; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REPRODUCIBILITY; SEROTONIN RELEASE;

ADULT; AGED; CARRIER PROTEINS; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0042421730     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.9.1223     Document Type: Article

References (41)

1. Jellinger K. New developments in the pathology of Parkinson's disease. Adv Neurol. 1990;53:1-16.
2. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol. 1994;35:494-498.
3. Graybiel AM, Hirsch EC, Agid Y. The nigrostriatal system in Parkinson's disease. Adv Neurol. 1990;53:17-29.
4. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol. 1999;156:138-148.
5. Brooks DJ, Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol. 2000;247(suppl 2):11/11-11/18.
6. Booij J, Tissingh G, Winogrodzka A, Van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999;26:171-182.
7. 3-paroxetine binding sites in putamen. Neurology. 1986;36:556-560.
8. Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB. Loss of brain-stem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res. 1990;510:104-107.
9. 3H]citalopram. Neuroscience. 1993;54:691-699.
10. Iacono RP, Kuniyoshi SM, Ahlman JR, Zimmerman GJ, Maeda G, Pearlstein RD. Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. J Neural Transm. 1997;104:451-459.
11. Heinz A, Ragan P, Jones DW, et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry. 1998;155:1544-1549.
12. Bergstrom KA, Kuikka JT, Ahonen A, Vanninen E. [123I] beta-CIT, a tracer for dopamine and serotonin re-uptake sites; preparation and preliminary SPECT studles in humans. J Nucl Biol Med. 1994;38:128-131.
13. Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [1-123]beta-CIT-binding kinetics in the human brain. J Neural Transmission. 1993;94:137-146.
14. 11C]McN5652: a serotonin transporter radioligand. J Cereb Blood Flow Metab. 1999;19:967-981.
15. Scheffel U, Szabo Z, Mathews WB, et al. In vivo detection of short- and long-term MDMA neurotoxicity: a positron emission tomography study in the living baboon brain. Synapse. 1998;29:183-192.
16. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 1998;352:1433-1437.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
18. Hamilton M. A rating scale in depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press; 1996.
20. Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical guide for grading the mental state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
22. Fahn S, Elton RL, and the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne BD, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillam Health Care Information; 1987:153-164.
23. UK Bromocriptine Research Group. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry. 1989;52:77-82.
24. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627-630.
25. Rew RK, Davis GP. NetCDF: an interface for scientific data access. IEEE Comput Graph App. 1990;10:76-82.
26. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr. 1992;16:620-633.
27. Rinne JO, Laihinen A, Nagren K, Ruottinen H, Ruotsalainen U, Rinne UK. PET examination of the monoamine transporter with [C-11]beta-CIT and [C-11]beta-CFT in early Parkinsons disease. Synapse. 1995;21:97-103.
28. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873-884.
29. Iida H, Kanno I, Miura S, Murakami M, Takahashi K, Uemura K, A determination of the regional brain/blood partition coefficient of water using dynamic positron emission tomography. J Cereb Blood Flow Metab. 1989;9:874-885.
30. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16:2529-2542.
31. Rinne JO, Bergman J, Ruottinen H, et al. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease. Synapse. 1999;31:119-124.
32. 11C]WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
33. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for β-CFT binding with positron emission tomography. Ann Neurol. 1999;45:601-610.
34. Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59:580-586.
35. Muller T, Farahati J, Kuhn W, et al. [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol. 1998;39:44-48.
36. 3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry. 1988;24:299-309.
37. 3H]WIN 35,428 to central dopamine transporters. Synapse. 1996;23:61-69.
38. Yeghiayan SK, Andersen SL, Baldessarini RJ. Lack of effect of chronic clorgy-line or selegiline on dopamine and serotonin transporters in rat caudate-putamen or nucleus accumbens septi. Neurosci Lett. 1997;236:147-150.
39. Graham D, Tahraoui L, Langer SZ. Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat. Neuropharmacology. 1987;26:1087-1092.
40. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559-1564.
41. 123I]beta-CIT. Mov Disord. 1999;14:436-442.